Literature DB >> 2979281

Cost of treating arthritis and NSAID-related gastrointestinal side-effects.

B S Bloom1.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are efficacious in the treatment of arthritis. However, side-effects particularly gastrointestinal toxicity, have been well documented with their use. Thus, in assessing total direct medical costs in the treatment of arthritis, the expenses involved in treating these side-effects must be taken into account. A retrospective analysis was undertaken of all direct medical costs related to care of a group of Medicaid recipients treated for arthritis during a 2-year period. Data were obtained from the Medicaid Management Information System of Washington, D.C., USA. The actual expenditure of treating arthritis as well as the medical costs of associated NSAID-induced gastrointestinal side-effects were determined. Arthritis treatment costs per quarter were found to be $145 per patient. Approximately 25% of the population experienced NSAID-related gastrointestinal side-effects requiring further medical care. Treatment of these adverse effects costs an additional $66 per quarter per patient, thus adding 45.5% to the cost of arthritis treatment. Pharmaceutical claims comprised 42.4% of total adverse drug reaction treatment costs, while the few hospital claims accounted for 37.9% and physician charges 19.7%. It has been estimated that in 1983 direct medical costs of arthritis treatment in the USA was $8.6 billion. By extrapolating the costs in this study, it can be estimated that a further $3.9 billion was spent on treating gastrointestinal side-effects of NSAIDs, making a total of $12.5 billion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979281     DOI: 10.1111/j.1365-2036.1988.tb00772.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy.

Authors:  B S Bloom
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

Review 2.  Epidemiology of NSAID-induced gastropathy.

Authors:  H Zeidler
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

Review 3.  The treatment of osteoarthritis.

Authors:  A C Jones; M Doherty
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 4.  NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.

Authors:  G D Champion; P H Feng; T Azuma; D E Caughey; K H Chan; S Kashiwazaki; H C Liu; A R Nasution; M Nobunaga; S Prichanond; T P Torralba; V Udom; D Utis; S R Wang; W S Wong; D J Yang; M C Yoo
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 5.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 6.  NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.

Authors:  Jørgen Naesdal; Kurt Brown
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Predictors of frequent oral analgesic use in rheumatoid arthritis.

Authors:  Esha das Gupta; Huey Shin Tee; Rajalingham Sakthiswary
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

8.  Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity.

Authors:  Michele Hummel; Terri Knappenberger; Meghan Reilly; Garth T Whiteside
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.